Seven Grand Managers LLC Takes Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Seven Grand Managers LLC bought a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $1,250,000.

A number of other hedge funds have also added to or reduced their stakes in CNTA. Avoro Capital Advisors LLC increased its stake in Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after buying an additional 5,808,080 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Centessa Pharmaceuticals by 20.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after buying an additional 1,449,000 shares during the last quarter. Commodore Capital LP increased its stake in Centessa Pharmaceuticals by 39.3% in the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after buying an additional 930,711 shares during the last quarter. TCG Crossover Management LLC increased its stake in Centessa Pharmaceuticals by 8.5% in the 3rd quarter. TCG Crossover Management LLC now owns 3,136,480 shares of the company’s stock valued at $76,060,000 after buying an additional 245,664 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Centessa Pharmaceuticals by 0.6% in the 3rd quarter. Franklin Resources Inc. now owns 2,558,414 shares of the company’s stock valued at $62,042,000 after buying an additional 14,875 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares in the company, valued at $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Karen M. Anderson sold 120,029 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,629,731.25. This represents a 65.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 309,112 shares of company stock worth $8,424,535. Corporate insiders own 4.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Needham & Company LLC lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $35.00 to $42.00 in a research note on Monday, April 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Wolfe Research lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Truist Financial lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target on the stock. in a research note on Monday, April 13th. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $39.77 on Thursday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The firm’s fifty day moving average price is $37.31 and its two-hundred day moving average price is $29.75. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $10.95 and a 1 year high of $40.26. The firm has a market capitalization of $5.93 billion, a P/E ratio of -22.22 and a beta of 1.13.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.